Skip to main content

Veppanu

Smiling older woman in a blue sweater resting her chin on her hand
Actor portrayal.

For those with ESR1m, ER+/HER2- metastatic breast cancer (mBC),
whose disease has progressed on endocrine therapy

Live vividly with VEPPANU

People taking VEPPANU lived longer without their cancer spreading

5.0 months median progression-free survival (PFS) with VEPPANU vs 2.1 months with fulvestrant

See what sets VEPPANU apart

View clinical trial results
Smiling woman with crossed arms, standing in a burgundy apron at a pottery studio, representing shared support for people living with metastatic breast cancer.
Actor portrayal.

Is VEPPANU right for me?

VEPPANU, a once-daily tablet, could work for you if you’re living with ER+/HER2- mBC, have progressed on at least one line of endocrine-based therapy, and have tested positive for an ESR1 mutation (ESR1m).
See how VEPPANU works

Is there a support program?

The dedicated team at RIGEL ONECARE can help support you throughout your journey.

Discover support & resources
Man and woman talking over coffee on a porch, representing support for those living with metastatic breast cancer.
Actor portrayal.

ER+=estrogen receptor-positive; ESR1=estrogen receptor 1; HER2-=human epidermal growth factor receptor 2-negative.